The FDA Authorized Emergency Use of Pfizer Paxlovid Pills Against COVID-19

Pfizer Received Emergency Use Authorization from the FDA for Paxlovid Pills for COVID-19

Good news for Pfizer (PFE), the U.S. FDA announced it has authorized the emergency use of PAXLOVID™ for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 (the virus that cause COVID-19) viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death.

The treatment includes nirmatrelvir, a novel main protease inhibitor originating in Pfizer’s laboratories, which was specifically designed to block the activity of the SARS-CoV-2 enzyme that the coronavirus needs for replication. 

From the Chairman and CEO of Pfizer

Leave a Reply